One billion doses of COVID vaccines possible next year, says CNBG
2020-12-14 16:07
A woman holds a small bottle labeled with a Vaccine COVID sticker and a medical syringe in this illustration taken on April , . PhotoAgencies    China National Biotec Group will have the capacity to produce  billion doses of COVID vaccines next year, said the president of the group, Chinanews reported.CNBG, a unit of stateowned pharmaceutical giant China National Pharmaceutical Group Sinopharm, has been recognized as a comprehensive biopharmaceutical enterprise focusing on human vaccines, blood products, medical aesthetics and animal healthcare. The companys two inactivated vaccine candidates are currently in phase III clinical trials in  countries and regions, with nearly , volunteers enrolled in the program, according to Yang Xiaoming, president of CNBG. As of Nov , a total of  COVID vaccine candidates have entered clinical trials worldwide, among which  have entered phase III clinical trials, he added. In China, four vaccine candidates are currently in phase III clinical trials, including three inactivated vaccines and one viruscarrier vaccine. It has been proved that the serum of the people vaccinated with the COVID vaccines developed by CNBG provides crossneutralization protection against multiple international epidemic strains, indicating the vaccines can play a protective role against novel coronavirus infection in many parts of the world, Yang said. At present, CNBGs two workshops in Beijing and Wuhan have a combined production capacity of  million doses of vaccine per year.